Adaptive Biotechnologies (ADPT) Research & Development (2018 - 2026)

Adaptive Biotechnologies has reported Research & Development for 9 years, with the latest figure at $26.3 million in Q1 2026.

• Quarterly Research & Development rose 8.85% year-over-year to $26.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95.7 million (up 29.91% YoY) and the FY2025 annual result came in at $93.8 million, up 10.63% from the prior year.
• Research & Development advanced to $26.3 million in Q1 2026 per ADPT's latest filing, from $21.8 million in the prior quarter.
• Over five years, Research & Development peaked at $55.4 million in Q4 2023 and troughed at $5.0 million in Q4 2024.
• A 5-year average of $27.7 million and a median of $26.1 million in 2022 frame the typical range for Research & Development.
• The sharpest annual moves came in 2024 and 2025: Research & Development plunged 90.99% in 2024, then jumped 335.43% in 2025.
• Over 5 years, Research & Development stood at $31.2 million in 2022, then soared by 77.58% to $55.4 million in 2023, then slumped by 90.99% to $5.0 million in 2024, then soared by 335.43% to $21.8 million in 2025, then climbed by 21.06% to $26.3 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $26.3 million, $21.8 million, and $23.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.